Stockscreener 앱 받기
6.77
4.38%
-0.31
시간 외 거래:
6.81
0.04
+0.59%
전일 마감가:
$7.08
열려 있는:
$6.79
하루 거래량:
3.09M
Relative Volume:
0.92
시가총액:
$700.81M
수익:
$45.97M
순이익/손실:
$-508.80M
주가수익비율:
-1.2354
EPS:
-5.48
순현금흐름:
$-382.65M
1주 성능:
-1.74%
1개월 성능:
-28.44%
6개월 성능:
-61.94%
1년 성능:
-72.87%
1일 변동 폭
$6.365
$6.91
1주일 범위
$5.90
$7.38
52주 변동 폭
$5.90
$28.18
Intellia Therapeutics Inc Stock (NTLA) Company Profile
명칭
Intellia Therapeutics Inc
전화
857-285-6200
주소
40 ERIE STREET, CAMBRIDGE, MA
NTLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
6.77 | 700.81M | 45.97M | -508.80M | -382.65M | -5.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.49 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
546.39 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
546.22 | 33.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
226.28 | 29.29B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
208.31 | 22.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 개시 | H.C. Wainwright | Buy |
| 2025-02-28 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-02-28 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-01-27 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-03-14 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-01-24 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-01-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-01 | 개시 | Citigroup | Sell |
| 2022-06-17 | 개시 | BMO Capital Markets | Market Perform |
| 2022-06-16 | 개시 | BofA Securities | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Outperform |
| 2022-02-18 | 개시 | William Blair | Outperform |
| 2022-02-07 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-31 | 개시 | Cowen | Outperform |
| 2022-01-07 | 개시 | Piper Sandler | Overweight |
| 2021-10-05 | 개시 | Guggenheim | Buy |
| 2021-09-24 | 개시 | Stifel | Buy |
| 2021-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-11 | 개시 | H.C. Wainwright | Buy |
| 2021-05-07 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-05-04 | 개시 | RBC Capital Mkts | Outperform |
| 2021-03-04 | 개시 | JMP Securities | Mkt Outperform |
| 2020-12-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | 개시 | Truist | Buy |
| 2020-10-14 | 개시 | Wells Fargo | Overweight |
| 2020-09-18 | 개시 | Goldman | Buy |
| 2020-02-28 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2020-02-14 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-11-01 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | 개시 | Robert W. Baird | Outperform |
| 2019-06-10 | 개시 | ROTH Capital | Neutral |
| 2019-05-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2018-11-02 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-10-29 | 개시 | Credit Suisse | Neutral |
| 2018-09-21 | 개시 | Raymond James | Mkt Perform |
| 2018-05-15 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2017-11-01 | 재확인 | Jefferies | Buy |
| 2017-06-22 | 재개 | Jefferies | Buy |
| 2017-03-28 | 개시 | Chardan Capital Markets | Buy |
| 2016-08-05 | 업그레이드 | Jefferies | Hold → Buy |
모두보기
Intellia Therapeutics Inc 주식(NTLA)의 최신 뉴스
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire
Intellia Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - GlobeNewswire Inc.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - PR Newswire
The Gross Law Firm Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineNTLA - PR Newswire
NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. - Bluefield Daily Telegraph
NTLA DEADLINE: ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA - TradingView
NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join - GlobeNewswire
Lost Money on Intellia Therapeutics, Inc. (NTLA)? Join Class Action Suit Seeking Recovery – ... - Bluefield Daily Telegraph
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - Morningstar
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple - Insider Monkey
NTLA Deadline: NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025 - openPR.com
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Intellia Therapeutics, Inc. to Contact the Firm Today! - markets.businessinsider.com
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA) Seeking Recovery for InvestorsContact Levi & Korsinsky - Morningstar
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - StreetInsider
Intellia Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Intellia adopts majority vote for director elections - Investing.com Australia
NTLA IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, - GlobeNewswire
NTLA IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – NTLA - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Intellia ... - Bluefield Daily Telegraph
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NTLA Investors are reminded of Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
Genome Engineering Market to Witness Remarkable Growth with - openPR.com
Class Action Filed Against Intellia Therapeutics, Inc. (NTLA)April 14, 2025 Deadline to JoinContact The Gross Law Firm - PR Newswire
Levi & Korsinsky Reminds Intellia Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025NTLA - ACCESS Newswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of - GlobeNewswire
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit ... - Bluefield Daily Telegraph
Faruqi & Faruqi Reminds Intellia Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - GlobeNewswire Inc.
NTLA DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics - Bluefield Daily Telegraph
Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph
Intellia stock plunges to 52-week low of $6.49 amid market challenges - Investing.com
NTLA Investors Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - markets.businessinsider.com
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN - Yahoo Finance
Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc.(NTLA) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
NTLA Investors Have Opportunity to Lead Intellia Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia begins phase 3 trial for gene-editing therapy - Investing.com Australia
Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy - Intellia Therapeutics
Revolutionary One-Shot Gene Therapy Enters Final Testing Phase for Fatal Nerve Disease - Stock Titan
Intellia Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsNTLA - Morningstar
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics - GlobeNewswire
NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against FMC, TransMedics, Intellia, and Merck and Encourages Investors to Contact the Firm - GlobeNewswire
Long Term Trading Analysis for (NTLA) - news.stocktradersdaily.com
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, A TOP-RANKED FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NTLA - TradingView
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 9.6%Should You Sell? - MarketBeat
Is Intellia Therapeutics, Inc. (NTLA) the Best Gene-Editing Stock to Buy? - Yahoo Finance
INTELLIA THERAPEUTICS, INC. (NASDAQ: NTLA) DEADLINE ALERT: - GlobeNewswire
Intellia Therapeutics Inc (NTLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.35%
10.53%
자본화:
|
볼륨(24시간):